170 related articles for article (PubMed ID: 37003478)
21. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
22. Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
Sargen MR; Cahoon EK; Lynch CF; Tucker MA; Goldstein AM; Engels EA
JAMA Dermatol; 2020 Dec; 156(12):1307-1314. PubMed ID: 33146669
[TBL] [Abstract][Full Text] [Related]
23. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
24. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.
Shalin SC; Lyle S; Calonje E; Lazar AJ
Histopathology; 2010 Jan; 56(1):133-47. PubMed ID: 20055911
[TBL] [Abstract][Full Text] [Related]
25. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.
Dores GM; Curtis RE; Toro JR; Devesa SS; Fraumeni JF
Cancer; 2008 Dec; 113(12):3372-81. PubMed ID: 18932259
[TBL] [Abstract][Full Text] [Related]
26. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
28. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
29. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
30. Metastatic Prostatic Adenocarcinoma in Patient With Muir-Torre Syndrome Misdiagnosed as Metastatic Sebaceous Carcinoma: Case Report and Systematic Literature Review.
Cattelan L; Abi-Rafeh J; Brimo F; Kazan R; Redpath M; Chergui M
Am J Dermatopathol; 2020 Sep; 42(9):700-705. PubMed ID: 32568842
[TBL] [Abstract][Full Text] [Related]
31. Sebaceous neoplasms and the Muir-Torre syndrome.
Elston DM
J Am Acad Dermatol; 2023 Dec; 89(6):1123. PubMed ID: 37172735
[No Abstract] [Full Text] [Related]
32. [Case report: Muir-Torre syndrome diagnosed from a sebaceoma mimicking an ulcerated breast cancer].
Demolin G; Romain M; Münschke A; Vandingenen T; Blaude MA; Van Craynest MP
J Gynecol Obstet Biol Reprod (Paris); 2016 Sep; 45(7):767-74. PubMed ID: 26321614
[TBL] [Abstract][Full Text] [Related]
33. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
[TBL] [Abstract][Full Text] [Related]
34. Sebaceous adenomas of the eyelid and Muir-Torre Syndrome.
Jagan L; Zoroquiain P; Bravo-Filho V; Logan P; Qutub M; Burnier MN
Br J Ophthalmol; 2015 Jul; 99(7):909-13. PubMed ID: 25595178
[TBL] [Abstract][Full Text] [Related]
35. Sebaceous carcinoma: controversies and their evidence for clinical practice.
Kibbi N; Worley B; Owen JL; Kelm RC; Bichakjian CK; Chandra S; Demirci H; Kim J; Nehal KS; Thomas JR; Poon E; Alam M
Arch Dermatol Res; 2020 Jan; 312(1):25-31. PubMed ID: 31471636
[TBL] [Abstract][Full Text] [Related]
36. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
37. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
38. [Challenges for Urologists in the Care of Patients with Lynch Syndrome: Example of A Patient with Muir-Torre Syndrome, A Subtype of Lynch Syndrome].
Löhmann C; Kächele V; Martinschek A; Sparwasser C
Aktuelle Urol; 2016 Apr; 47(2):144-7. PubMed ID: 26509248
[TBL] [Abstract][Full Text] [Related]
39. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination.
Shiki M; Hida T; Sugano K; Kaneko R; Kamiya T; Sakurai A; Yamashita T
Eur J Dermatol; 2017 Feb; 27(1):54-58. PubMed ID: 28120777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
